1/28
06:41 pm
lsta
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
1/28
02:23 pm
lsta
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
1/27
08:00 am
lsta
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
High
Report
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
1/22
12:00 am
lsta
All-Cash Buyout Sparks Breakout Move in Biotech Name [Globe and Mail, The (Toronto, Canada)]
Low
Report
All-Cash Buyout Sparks Breakout Move in Biotech Name [Globe and Mail, The (Toronto, Canada)]
1/21
02:46 pm
lsta
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
Low
Report
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
1/21
11:17 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
Low
Report
Lisata Therapeutics (NASDAQ:LSTA) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
1/21
11:00 am
lsta
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasda
Low
Report
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc. (Nasda
1/21
07:00 am
lsta
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
High
Report
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
11/12
06:43 am
lsta
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Lisata Therapeutics (NASDAQ:LSTA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.